#United States #Austin #Prostate Cancer #Francis Medical #Vanquish System

Francis Medical's Innovative Leap in Prostate Cancer Treatment

Francis Medical, Inc., a leading name in the medical device industry, has achieved a remarkable milestone by conducting the first commercial procedure with its Vanquish® Water Vapor Ablation System. This pioneering treatment took place at the Pinnacle Surgery Center in Austin, Texas, and was performed by Dr. Eric Giesler of Urology Austin. The patient had been diagnosed with intermediate-risk localized prostate cancer, aligning with the profiles studied in the company's pivotal VAPOR 2 clinical trial.

The Vanquish System employs an innovative, minimally invasive approach, utilizing thermal water vapor to ablate targeted prostate tissue. This technology represents a significant advancement over traditional treatments, which often come with a risk of adverse side effects such as urinary incontinence and erectile dysfunction. The system received its 510(k) clearance from the U.S. Food and Drug Administration (FDA) in November 2025, supported by promising 12-month follow-up data from the initial 110 patients in the VAPOR 2 study.

The VAPOR 2 study encompasses a multicenter, single-arm trial involving 235 patients across 26 clinical sites in the U.S. Initial procedures commenced in February 2025, with ongoing follow-up intended to strengthen the case for a premarket approval submission for broader use in managing localized prostate cancer. Dr. Giesler expressed satisfaction with the technology, emphasizing its reliability and the potential reduction in risks of post-treatment complications for patients.

Notably, the data from the VAPOR 2 study reveals that 91% of participants experienced the elimination of targeted biopsy-confirmed intermediate-risk prostate cancer after a single procedure. The initial findings also indicate an encouraging absence of serious device-related adverse events, reinforcing the Vanquish System's safety profile.

Furthermore, patients engaged in the study reported minimal to no discomfort post-procedure, with an impressive 93% expressing high satisfaction with their treatment outcome. These figures underscore the feasibility of the Vanquish System as a preferable option compared to traditional therapies.

Dr. Christopher Dixon, Chief Medical Officer of Francis Medical, highlighted the achievement as the result of years of dedicated innovation and collaboration. He articulated the system's potential to impact patients' lives positively without compromising their quality of life, a crucial consideration in the field of urological cancer treatment.

The Vanquish Water Vapor Ablation System stands out as a beacon of hope for many men facing the daunting challenges of prostate cancer. Developed in remembrance of Francis Hoey, the father of the company's founder, Michael Hoey, who experienced the burdensome side effects of conventional treatments, this technology embodies a commitment to changing the narrative surrounding prostate cancer care.

As patients and healthcare professionals alike look to embrace minimally invasive therapies, the Vanquish System offers an exciting glimpse into the future of prostate cancer treatment. With favorable outcomes and an emphasis on patient quality of life, the potential for this technology extends beyond mere clinical efficacy, striving for a transformative experience in the realm of prostate health management.

For further insights on Francis Medical and their pioneering approach to treatment, visit their official website or reach out to their team directly.

About Francis Medical

Francis Medical is dedicated to developing advanced urological cancer treatments that are both effective against the disease and gentle on patients. With a mission rooted in compassion and innovation, the company is committed to offering alternatives that prioritize patient well-being throughout their cancer journey.

For more information please visit www.francismedical.com or contact via phone at (763) 951-0370.